Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATI-50002 for eyebrow loss in alopecia areata
NCT03551821Phase 2Completed
- Sponsor
- Aclaris Therapeutics, Inc.
- Start
- Apr 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ifidancitinib in alopecia areata, alopecia universalis (AU) and alopecia totalis (AT), sponsored by Aclaris Therapeutics, Inc. Primary endpoint: Clinician's Eyebrow Assessment at 6 months. Started Apr 2018; status: completed.
02
Drugs
ifidancitinib
03
Conditions
alopecia areataalopecia universalis (AU)alopecia totalis (AT)
Beyond the preview
Go deeper on NCT03551821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03551821.